RI OkuStim® is one of the very first outpatient therapies for RP, and its efficacy has been demonstrated in clinical trials.
Research results show that the activation of several so-called neuroprotective growth factors on the retina - by means of electrical stimulation - can have a retention effect on the dying retinal cells. Thus, the degeneration of affected cells can also be reduced. Both contribute to enabling longer cellular function of the remaining cells. The retention can, for example, be measured or examined by a so-called electroretinography (ERG). This represents the electrical activity of the cells in response to light stimuli.
With RI OkuStim® RP patients have a therapy option which is considered safe by a panel of experts consisting of doctors and representatives from the patient organisation PRO RETINA on the basis of current studies.
To date, RI OkuStim® therapy has been applied to ca.150 patients, including over long periods of time, for study purposes.
(1) Schatz et al.: Transcorneal Eletrical Stimulation for Patients with Retinitis pigmentosa: A Prospective, Randomized, Sham-Controlled Exploratory Study. IOVS, June 2011, vol. 52, no 7, 4485-4496.
(2) Schatz et al.: Transcorneal Eletrical Stimulation for Patients with Retinitis Pigmentosa: A Prospective, Randomized, Sham-Controlled Follow-up Study Over 1 Year. IOVS, Jan 2017, vol. 58, no 1 257-296.
(3) TESOLA observational study (results presented for scientific discussion at the Euretina in September 2015 and the WOC in February 2016. Paper in preparation.)